Comparison of Aripiprazole and Risperidone on ADHD

Comparison of Aripiprazole and Risperidone in ADHD Children Under Six Years referred to Taleghani Hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015123025768N1

Enrollment

Registered

2016-04-24

Start date

2016-05-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit-Hyperactivity Disorder. Disturbance of activity and attention. Incl: Attention deficit: disorder with hyperactivity. hyperactivity disorder. syndrome with hyperactivity

Interventions

Intervention 1: Aripiprazole, Duration of intervention: 12 week. Minimum dose: 1.25 milligram, this dose can be increased 1.25 milligram each week due to clinical response and side effects up to 6.2

Treatment - Drugs

Aripiprazole, Duration of intervention: 12 week. Minimum dose: 1.25 milligram, this dose can be increased 1.25 milligram each week due to clinical response and side effects up to 6.25 milligram per

Risperidone, Duration of intervention: 12 week. Minimum dose: 0.25 milligram, this dose can be increased 0.25 milligram each week due to clinical response and side effects up to 1.25 milligram.

Eligibility

Sex/Gender

All

Age

3 Years to 5 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Children between 3 to 6 years old who are diagnosed with ADHD by the criteria of DSM-IV-TR for the first time after visiting Psychology Clinic of Taleghani Educational Hospital in Gorgan, Iran. Exclusion criteria: Concurrent diagnosis of one of the following disorders with another one or more which led patients to be excluded from the research: BMD, Mental retardation, Psychotic and Autistic disorders, Epilepsy; every inhibition of having oral medicine or conditions causing interactions with the treatment; history of psychotropic drugs treatment within the last 2 weeks; and obesity.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ADHD syptoms changes. Timepoint: Baseline and then 2 week, 4 week, 8 week and 12 week after treatment began. Method of measurement: Strengths and Difficulties Questionnaire(SDQ), ADHD-RS Questionnaire, C-GAS Questionnaire.	—

Secondary

Measure	Time frame
Comparison of side effects. Timepoint: 2 week, 4 week, 8 week and 12 week after treatment began. Method of measurement: Side Effects Checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFiroozeh Derakhshanpoor

Psychiary office of gorgan university of medical science.

f.derakhshanpour@yahoo.com+98 17 3234 4198

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026